According to filings with the U.S. Securities and Exchange Commission, Immusoft is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Sean Ainsworth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immusoft
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patients own cells. The company is developing a technology platform called Immune System Programming (ISP), which modifies a patients B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

To learn more about Immusoft, visit http://immusoft.com/
Company Linkedin Page: https://www.linkedin.com/company/immusoft/

Contact:
Sean Ainsworth, Chief Executive Officer
206-397-0028
https://www.linkedin.com/in/sean-ainsworth-ba69ba/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.